[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophagogastric-junction-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophagogastric-junction-disorder":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100397450","circulating-biomarkers-for-individualized-surgical-therapy-in-gastroesophageal-cancer---phase-1-100397450",false,"NCT04455282","CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1","CIRCULATE1","Inclusion Criteria:\n\n* histologically proven adenocarcinoma of the GEJ type I and II, resectable, non-metastatic tumor\n* age ≥18\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2,\n* American Society of Anesthesiologists (ASA) \\\u003C 4.\n* pre-treatment stage cT1N+ M0 or cT2-4a N0\u002FN+, M0 GEJ type I and II adenocarcinomas can be included. In case of stage cT4a, curative resectability has to be explicitly verified by the local surgical investigator prior inclusion.\n* Written informed consent and the ability to understand the nature of the study and the study-related procedures and to comply with them has to be ensured.\n\nExclusion Criteria:\n\n* tumors of squamous, adenosquamous or other non-adenocarcinoma histology\n* patients with inoperable or metastatic GEJ type I and II adenocarcinoma, GEJ type I and II adenocarcinoma staged cT1N0 and cT4b, GEJ type I and II cT4a evaluated as not curatively resectable by the local surgical investigator\n* unsigned informed consent","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This is an exploratory observational biomarker study in approximately 100 eligible patients with resectable adenocarcinomas of the esophagus and gastro- esophageal junction (GEJ) type I-II (GEAC) to investigate the difference deletion frequency of circulating tumor cells (CTCs) between peripheral veins and tumor-draining veins (primary endpoint), prognostic value, relevance of a set of two additional blood-based biomarkers analyzed from a single blood sampling tube (secondary endpoints). The underlying hypothesis is that the biomarker alone or in combination improve preoperative staging and help to identify patients at risk for metastasis. This should enable a better stratification of GEAC patients to neo-adjuvant treatment, (intensified) peri-operative treatment, or even surgery alone, in selected cases. The data of the CIRCULATE study shall be used design subsequent studies testing the predictive role of these biomarkers for surgical management. Patients will provide blood samples and lymphatic fluid during the operation and annual blood samples during clinical follow up of 5 years.",[24,25],"Cancer of Esophagus","Esophagogastric Junction Disorder",[27,28,29,30],"Circulating Biomarkers","CTC","tdEVs","ctDNA","RECRUITING","2024-03-07",{"date":34,"type":35},"2024-03-08","ACTUAL",{"date":37,"type":35},"2021-02-01",{"date":39,"type":20},"2028-01-30",{"name":41,"class":42},"Heinrich-Heine University, Duesseldorf","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100359574","phase-3-perioperative-combination-chemotherapy-versus-chemoradiation-for-locally-advanced-egj-adenocarcinoma-100359574","NCT03961841","Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma","A Randomised Controlled Trial Comparing Perioperative FLOT, FOLFOX and Preoperative Chemoradiation for Locally Advanced Esophagogastric Junction Adenocarcinoma","Inclusion Criteria:\n\n* informed consensus of the enrolled patients\n* from 18 to 75 years old\n* proven to be primary adenocarcinoma of EGJ\n* pre-operative staging cT3-4N+M0\n* no prior other chemotherapy and\u002For radiation against the disease\n* normal function of all other vital organs including heart,liver ,kidney and so on\n* Eastern Cooperative Oncology Group performance status: 0\\~2\n\nExclusion Criteria:\n\n* history of other malignancy\n* allergic reaction to capecitabine or oxaliplatin\n* enrolled in other clinical trials\n* abnormal GI tract function\n* dysfunction of other organs\n* pregnant or lactating females ,or refuse to receive contraception measures during chemotherapy\n* other situations judged as not adaptive to the study by investigators","75 Years",{"count":52,"type":20},900,"INTERVENTIONAL",[55],"PHASE3","Patients with histologically confirmed esophagogastric junction adenocarcinoma with pre-operative staging cT3-4N+M0，aged between 18-75 years old, with adequate organ function and having an Eastern Cooperative Oncology Group performance status score ≤2, are randomized in a 1:1:1 ratio to receive neoadjuvant chemoradiotherapy with DT46-50Gy plus concomitant weekly oxaliplatin and 5-Fu, perioperative chemotherapy of FLOT regimen or FOLFOX regimen. The primary end point is disease free survival (DFS), and secondary end point is 5-year overall survival (OS), pathological complete remission (pCR) and treatment safety. The final study analytics are to be conducted at the end of the 5th year after the last patient's enrollment.",[25,58],"Neoplasms","NOT_YET_RECRUITING","2019-12-19",{"date":62,"type":35},"2019-12-23",{"date":64,"type":20},"2020-06",{"date":66,"type":20},"2029-08",{"name":68,"class":42},"Sixth Affiliated Hospital, Sun Yat-sen University"]